Skip to main content
. 2022 Sep 22;19(19):11985. doi: 10.3390/ijerph191911985

Figure 1.

Figure 1

Uncertainty in the cost-effectiveness results (health and social care perspective). (A) Cost-Effectiveness Plane: Bootstrapped ICERs (PoMeT vs. TAU); (B) Cost-Effectiveness Acceptability Curve (CEAC): Probability of PoMeT being cost-effective in comparison to TAU at different willingness-to-pay thresholds for QALY gained.